Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Moderna, COVID-19
Moderna Stock Jumps on Canadian Government's Approval of Updated COVID-19 Vaccine
Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 vaccine.Moderna's Spikevax KP.2 targets the KP.2 variant of the virus.The U.S. Food and Drug Administration has also approved the shot,
COVID-19 2024 fall guide: Everything Canadians should know about new Moderna vaccine, current variants and more
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in the fall of 2024." The organization recommends a six-month interval between COVID vaccines, "with a minimum of three months from the last dose."
Moderna's updated COVID-19 vaccine approved in Canada
Health Canada has authorized Moderna's updated COVID-19 vaccine to roll out in fall immunization campaigns. The new Spikevax formula targets the KP.2 subvariant, one of the latest offshoots of the Omicron variant of the virus that causes COVID-19.
3h
Moderna Inc. stock underperforms Thursday when compared to competitors
Shares of Moderna Inc. MRNA slipped 2.63% to $68.02 Thursday, on what proved to be an all-around favorable trading session ...
3h
Behind the Scenes of Moderna's Latest Options Trends
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...
4d
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
5d
on MSN
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...
6d
on MSN
Moderna’s spending cuts, pipeline shakeup leave doubts about a rebound, analysts say
Moderna’s cost-reduction plans, pipeline cuts and reined-in financial guidance, unveiled Thursday, triggered a wave of ...
13h
RBC Capital Keeps Their Hold Rating on Moderna (MRNA)
RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $75.00. The ...
bovnews
5h
Moderna Inc (MRNA) Stock Price Reaches $69.86: What Factors Are Influencing This Level?
Moderna Inc (MRNA) stock saw a decline, ending the day at $69.86 which represents a decrease of $-2.13 or -2.96% from the prior close of $71.99. The stock opened at $72.19 and touched a low of $69.82 ...
3d
Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early Human Trial Data
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
7d
Moderna forecasts lower sales next year, shares near four-year low
Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...
1d
Moderna Inc. stock underperforms Wednesday when compared to competitors
Shares of Moderna Inc. MRNA shed 2.96% to $69.86 Wednesday, on what proved to be an all-around dismal trading session for the ...
Investor's Business Daily on MSN
3d
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
COVID
S&P 500 Index
MRNA
Trade
Jim Cramer
Feedback